封面
市場調查報告書
商品編碼
2178974

人工智慧驅動的數位病理平台市場預測至2034年——全球部署模式、平台組件、人工智慧功能、臨床應用、最終用戶和區域分析

AI-Driven Digital Pathology Platforms Market Forecasts to 2034 - Global Analysis By Deployment Mode, Platform Component, AI Functionality, Clinical Application, End User and By Geography

出版日期: | 出版商: Stratistics Market Research Consulting | 英文 300+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據,全球人工智慧驅動的數位病理平台市場預計將在 2026 年達到 25 億美元,在預測期內以 17.1% 的複合年成長率成長,到 2034 年達到 87 億美元。

人工智慧驅動的數位病理平台整合了人工智慧、全切片成像、數位影像管理和先進的分析技術,以支援組織檢查、疾病檢測、生物標記評估和病理工作流程的自動化。癌症發生率的上升、病理工作量的增加以及對準確快速診斷需求的成長正在推動市場發展。深度學習、計算病理學、雲端影像分析和預測分析的進步正在提升診斷能力。對數位醫療基礎設施、精準腫瘤學和人工智慧驅動的檢測工作流程的投資增加,正在為全球的醫院、診斷實驗室、製藥公司和研究機構創造巨大的商機。

癌症負擔日益加重,對高效數位病理診斷的需求也日益成長。

癌症負擔日益加重,以及對高效數位病理診斷的需求不斷成長,正在推動市場擴張。醫療機構面臨病理工作量增加、診斷複雜性上升以及專業病理醫師短缺的困境。人工智慧驅動的數位病理平台透過輔助自動化組織分析、腫瘤識別、生物標記評分和病例優先排序,幫助提高檢查室效率。全切片成像和數位診斷工作流程的日益普及也促進了其應用。對精準腫瘤學、病理觀察標準化以及更快診斷結果的需求不斷成長,進一步推動了醫療和研究機構對人工智慧驅動的病理解決方案的投資。

數位病理基礎設施高成本,臨床人工智慧檢驗面臨挑戰。

數位病理基礎設施的高成本以及臨床人工智慧檢驗的挑戰正在限制市場成長。實施人工智慧病理系統需要全玻片掃描器、大容量影像儲存、高效能運算以及與實驗室資訊系統 (LIS) 的整合。染色方案、掃描器技術和組織製備方面的差異都會影響演算法效能。臨床檢驗和法規核准流程增加了開發和部署成本。互通性限制和對工作流程變更的抵觸情緒也是其他挑戰。小規模檢查室在從傳統顯微鏡過渡到全數位化病理環境時可能會面臨財務壓力。

擴展人工智慧驅動的生物標記分析和精準腫瘤病理平台

人工智慧驅動的生物標記分析和精準腫瘤病理平台的擴展帶來了巨大的成長機會。先進的計算病理系統能夠量化組織特徵、識別腫瘤模式,並輔助解讀用於標靶癌症治療的生物標記。將病理影像與基因組和臨床資訊整合,可以實現更全面的疾病評估。人工智慧開發商、製藥公司和診斷檢查室之間的夥伴關係正在推動商業化進程。對伴隨診斷、數位病理研究和自動化生物標記評分的投資增加,預計將擴大其在腫瘤學、藥物研發和轉化醫學領域的應用。

演算法偏差、診斷可靠性風險以及不斷變化的監管要求

演算法偏差、診斷可靠性風險以及不斷變化的監管要求威脅著市場擴張。人工智慧病理系統應用於使用不熟悉的掃描儀、染色方法或不同患者群體產生的影像時,可能會產生不一致的結果。誤診和臨床檢驗不足會導致病人安全問題和潛在的法律責任。醫療機構必須解決網路安全、敏感患者資料保護和監管合規性問題。數位病理供應商之間的競爭可能會加劇價格壓力。技術提供者必須展現出強大的臨床性能、透明的檢驗、互通性以及病理學家有效的監督,才能維持市場信心。

新型冠狀病毒(COVID-19)的影響:

新冠疫情凸顯了遠距離診斷協作和靈活體組織切片查室操作的必要性,加速了人們對數位病理學的興趣。醫療機構准入限制促使人們投資於數位切片共用、遠距病理診斷和影像管理平台。然而,設備供應鏈中斷和醫療預算緊張導致一些基礎設施項目延長。隨後,數位病理工作流程的擴展為人工智慧影像分析和自動化診斷支援創造了機會。人們對檢查室韌性、遠距會診和醫療數位化的日益關注,將繼續推動市場發展。

在預測期內,基於雲端的平台細分市場預計將佔據最大佔有率。

由於其可擴展的影像儲存、集中式人工智慧處理以及跨分散式病理網路的可存取性,預計在預測期內,基於雲端的平台細分市場將佔據最大的市場佔有率。雲端基礎設施使醫療機構能夠管理大規模全切片影像資料集並部署高級分析應用程式,而無需維護大規模的本地運算資源。基於訂閱的平台支援靈活的部署和軟體更新。對遠端病理協作和整合檢查室工作流程日益成長的需求正在推動其應用。不斷提高的雲端安全性、資料互通性和人工智慧處理能力進一步鞏固了該細分市場的市場地位。

預計在預測期內,預測病理學和預後分析領域將呈現最高的複合年成長率。

在預測期內,預測病理學和預後分析領域預計將呈現最高的成長率,這主要得益於市場對能夠從數位化組織樣本中提取預後資訊的AI工具的需求不斷成長。先進的模型可以分析組織學模式、腫瘤微環境和組織特徵,從而支持疾病風險評估和治療方案。精準腫瘤學和計算病理學研發投入的增加正在推動該領域的發展。與分子和臨床資料集的整合正在擴展分析能力。診斷檢查室、製藥公司和AI開發商之間更深入的合作有望加速該領域的成長。

市佔率最大的地區:

在預測期內,北美預計將佔據最大的市場佔有率,這主要得益於其先進的醫療保健基礎設施、對人工智慧的大量投資以及數位病理技術的日益普及。美國正透過其完善的診斷實驗室、大學醫院、製藥公司和醫療技術供應商推動區域發展。對腫瘤診斷和精準醫療日益成長的需求正在促進其應用。完善的研究經費、數位醫療保健基礎設施以及病理人工智慧開發人員與臨床機構之間的合作正在強化商業化進程。

複合年成長率最高的地區:

在預測期內,亞太地區預計將呈現最高的複合年成長率,這主要得益於醫療基礎設施的不斷改進、癌症診斷需求的成長以及對數位病理學投資的持續增加。中國、印度、日本、韓國和澳洲正在推動醫學影像基礎設施建設、檢查室數位化和人工智慧研究。龐大的患者群體和日益成長的病理工作量正在推動自動化診斷解決方案的普及。對醫療技術投資的增加、診斷檢查室網路的擴展以及政府的數位健康舉措都在支持該地區的發展。對高度擴充性的人工智慧病理平台的需求不斷成長,預計將加速市場成長。

免費客製化服務:

所有購買此報告的客戶均可享受以下免費自訂選項之一:

  • 企業概況
    • 對其他市場參與者(最多 3 家公司)進行全面分析
    • 對主要公司進行SWOT分析(最多3家公司)
  • 區域細分
    • 根據客戶要求,我們可以提供主要國家的市場估算和預測,以及複合年成長率(註:需經可行性確認)。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對領先公司進行基準分析。

目錄

第1章執行摘要

  • 市場概覽及主要亮點
  • 促進因素、挑戰與機遇
  • 競爭格局概述
  • 戰略洞察與建議

第2章:研究框架

  • 研究目標和範圍
  • 相關人員分析
  • 研究假設和限制
  • 調查方法

第3章 市場動態與趨勢分析

  • 市場定義與結構
  • 主要市場促進因素
  • 市場限制與挑戰
  • 投資成長機會和重點領域
  • 產業威脅與風險評估
  • 技術與創新展望
  • 新興市場/高成長市場
  • 監管和政策環境
  • 新冠疫情的影響及復甦前景

第4章:競爭環境與策略評估

  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭公司之間的競爭
  • 主要公司市佔率分析
  • 產品基準評效和效能比較

第5章 全球人工智慧驅動的數位病理平台市場:按部署模式分類

  • 基於雲端的平台
  • 本地部署平台
  • 混合平台

第6章 全球人工智慧驅動的數位病理平台市場:按平台組件分類

  • 軟體
    • 人工智慧病理影像分析軟體
    • 數位病理影像管理平台
    • 整合式人工智慧病理工作流程平台
  • 服務
    • 實施和整合服務
    • 培訓和諮詢服務
    • 支援和維護服務

第7章 全球人工智慧驅動的數位病理平台市場:按人工智慧功能分類

  • 組織和細胞的自動檢測
  • 腫瘤檢測與分類
  • 組織學分級和定量
  • 生物標記檢測和評分
  • 全幻燈片影像分析
  • 人工智慧驅動的病例篩選和優先排序
  • 預測病理和預後分析
  • 病理工作流程自動化
  • 其他人工智慧功能

第8章 全球人工智慧驅動的數位病理平台市場:按臨床應用分類

  • 腫瘤病理學
    • 乳癌病理
    • 攝護腺癌的病理學
    • 其他癌症病理
  • 感染疾病病理學
  • 發炎和自體免疫疾病的病理學
  • 神經病理學
  • 血液病理學
  • 移植病理學
  • 藥物發現與轉化研究
  • 其他臨床用途

第9章 全球人工智慧驅動的數位病理平台市場:按最終用戶分類

  • 醫院和醫療保健系統
  • 診斷和檢測機構
  • 大學醫院
  • 製藥和生物技術公司
  • 受託研究機構
  • 研究機構
  • 其他最終用戶

第10章 全球人工智慧驅動的數位病理平台市場:按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 比利時
    • 瑞典
    • 瑞士
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 馬來西亞
    • 新加坡
    • 越南
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
    • 秘魯
    • 其他南美國家
  • 世界其他地區(RoW)
    • 中東
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 以色列
      • 其他中東國家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲國家

第11章 策略市場資訊

  • 工業價值網路和供應鏈評估
  • 空白區域和機會地圖
  • 產品演進與市場生命週期分析
  • 通路、經銷商和打入市場策略的評估

第12章 產業趨勢與策略舉措

  • 併購
  • 夥伴關係、聯盟和合資企業
  • 新產品發布和認證
  • 擴大生產能力和投資
  • 其他策略舉措

第13章:公司簡介

  • PathAI, Inc.
  • Proscia Inc.
  • Ibex Medical Analytics Ltd.
  • Aiforia Technologies Plc
  • Visiopharm A/S
  • Indica Labs, Inc.
  • Mindpeak GmbH
  • Qritive
  • Owkin, Inc.
  • Nucleai, Inc.
  • Techcyte, Inc.
  • Deep Bio Inc.
  • Tempus AI, Inc.
  • Koninklijke Philips NV
  • F. Hoffmann-La Roche Ltd.
  • Leica Biosystems
  • Hamamatsu Photonics KK
  • Sectra AB
Product Code: SMRC40907

According to Stratistics MRC, the Global AI-Driven Digital Pathology Platforms Market is accounted for $2.5 billion in 2026 and is expected to reach $8.7 billion by 2034 growing at a CAGR of 17.1% during the forecast period. AI-Driven Digital Pathology Platforms integrate artificial intelligence, whole-slide imaging, digital image management, and advanced analytical technologies to support tissue examination, disease detection, biomarker assessment, and pathology workflow automation. Increasing cancer prevalence, growing pathology workloads, and demand for accurate and timely diagnoses are driving market expansion. Technological advancements in deep learning, computational pathology, cloud-based image analysis, and predictive analytics are improving diagnostic capabilities. Growing investments in digital healthcare infrastructure, precision oncology, and AI-assisted laboratory workflows are creating significant opportunities across hospitals, diagnostic laboratories, pharmaceutical companies, and research institutions worldwide.

Market Dynamics:

Driver:

Increasing cancer burden and demand for efficient digital pathology diagnostics

Increasing cancer burden and demand for efficient digital pathology diagnostics are driving market expansion. Healthcare organizations face growing pathology workloads, increasing diagnostic complexity, and shortages of specialized pathologists. AI-driven digital pathology platforms support automated tissue analysis, tumor identification, biomarker scoring, and case prioritization, helping improve laboratory productivity. Growing adoption of whole-slide imaging and digital diagnostic workflows encourages implementation. Increasing demand for precision oncology, standardized pathology interpretation, and faster diagnostic turnaround further strengthens investment in AI-enabled pathology solutions across healthcare and research institutions.

Restraint:

High digital pathology infrastructure costs and challenges in clinical AI validation

High digital pathology infrastructure costs and challenges in clinical AI validation restrain market growth. Implementing AI-enabled pathology systems requires whole-slide scanners, substantial image storage capacity, high-performance computing, and integration with laboratory information systems. Variations in staining protocols, scanner technologies, and tissue preparation can affect algorithm performance. Clinical validation and regulatory approval processes increase development and deployment costs. Limited interoperability and resistance to workflow changes create additional challenges. Smaller laboratories may face financial constraints when transitioning from conventional microscopy to fully digital pathology environments.

Opportunity:

Expansion of AI-powered biomarker analysis and precision oncology pathology platforms

Expansion of AI-powered biomarker analysis and precision oncology pathology platforms presents significant growth opportunities. Advanced computational pathology systems can quantify tissue characteristics, identify tumor patterns, and support biomarker interpretation for targeted cancer therapies. Integration of pathology images with genomic and clinical information enables more comprehensive disease assessment. Partnerships between AI developers, pharmaceutical companies, and diagnostic laboratories support commercialization. Increasing investment in companion diagnostics, digital pathology research, and automated biomarker scoring is expected to expand adoption across oncology, drug development, and translational medicine.

Threat:

Algorithmic bias, diagnostic reliability risks, and evolving regulatory requirements

Algorithmic bias, diagnostic reliability risks, and evolving regulatory requirements threaten market expansion. AI pathology systems may produce inconsistent results when applied to images generated using unfamiliar scanners, staining methods, or patient populations. Diagnostic errors and inadequate clinical validation can create patient safety concerns and potential liability. Healthcare organizations must address cybersecurity, sensitive patient data protection, and regulatory compliance requirements. Increasing competition among digital pathology vendors may create pricing pressure. Technology providers must demonstrate robust clinical performance, transparent validation, interoperability, and effective pathologist oversight to maintain market confidence.

Covid-19 Impact:

The COVID-19 pandemic accelerated interest in digital pathology by highlighting the need for remote diagnostic collaboration and flexible laboratory operations. Restrictions on physical access to healthcare facilities encouraged investment in digital slide sharing, remote pathology review, and image management platforms. However, equipment supply chain disruptions and healthcare budget pressures delayed certain infrastructure projects. The subsequent expansion of digital pathology workflows has created opportunities for AI-assisted image analysis and automated diagnostic support. Growing emphasis on laboratory resilience, remote consultation, and healthcare digitalization continues to support market development.

The cloud-based platforms segment is expected to be the largest during the forecast period

The cloud-based platforms segment is expected to account for the largest market share during the forecast period due to scalable image storage, centralized AI processing, and accessibility across distributed pathology networks. Cloud infrastructure enables healthcare organizations to manage large whole-slide image datasets and deploy advanced analytical applications without maintaining extensive local computing resources. Subscription-based platforms support flexible implementation and software updates. Increasing demand for remote pathology collaboration and integrated laboratory workflows encourages adoption. Improvements in cloud security, data interoperability, and AI processing capabilities further strengthen the segment's market position.

The predictive pathology & prognostic analytics segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the predictive pathology & prognostic analytics segment is predicted to witness the highest growth rate due to increasing demand for AI tools capable of extracting prognostic insights from digitized tissue samples. Advanced models can analyze histological patterns, tumor microenvironments, and tissue characteristics to support disease risk assessment and treatment planning. Growing investment in precision oncology and computational pathology research encourages development. Integration with molecular and clinical datasets is expanding analytical capabilities. Increasing collaboration between diagnostic laboratories, pharmaceutical companies, and AI developers is expected to accelerate segment growth.

Region with largest share:

During the forecast period, the North America is expected to hold the largest market share due to advanced healthcare infrastructure, substantial investment in artificial intelligence, and growing adoption of digital pathology technologies. The United States leads regional development through established diagnostic laboratories, academic medical centers, pharmaceutical companies, and healthcare technology providers. Increasing demand for oncology diagnostics and precision medicine supports implementation. Established research funding, digital healthcare infrastructure, and collaborations between pathology AI developers and clinical institutions strengthen commercialization.

Region with highest CAGR:

Over the forecast period, the Asia Pacific is anticipated to exhibit the highest CAGR, supported by expanding healthcare infrastructure, increasing cancer diagnostic demand, and growing investment in digital pathology. China, India, Japan, South Korea, and Australia are advancing medical imaging infrastructure, laboratory digitalization, and artificial intelligence research. Large patient populations and increasing pathology workloads encourage adoption of automated diagnostic solutions. Growing healthcare technology investment, expanding diagnostic laboratory networks, and government digital health initiatives support regional development. Increasing demand for scalable AI-powered pathology platforms is expected to accelerate market growth.

Key players in the market

Some of the key players in the AI-Driven Digital Pathology Platforms Market include PathAI, Inc., Proscia Inc., Ibex Medical Analytics Ltd., Aiforia Technologies Plc, Visiopharm A/S, Indica Labs, Inc., Mindpeak GmbH, Qritive, Owkin, Inc., Nucleai, Inc., Techcyte, Inc., Deep Bio Inc., Tempus AI, Inc., Koninklijke Philips N.V., F. Hoffmann-La Roche Ltd., Leica Biosystems, Hamamatsu Photonics K.K., and Sectra AB.

Key Developments:

In October 2026, Agilent Technologies announced a definitive agreement to acquire Proscia Inc., a provider of enterprise digital pathology software, for $240 million in cash at closing and up to an additional $30 million in performance-based payments. The proposed acquisition is intended to strengthen Agilent's pathology portfolio by integrating digital image management and AI-enabled software with its existing laboratory technologies.

In October 2026, Aiforia Technologies Plc announced a commercial collaboration with PathAI, Inc. to expand access to AI-powered pathology diagnostics through PathAI's AISight Marketplace. The agreement enables laboratories using PathAI's digital pathology image management platform to access Aiforia's AI applications within established case review workflows.

In September 2026, Proscia Inc. announced that Unilabs was deploying its Concentriq digital pathology platform across multiple European markets. The initiative connects pathologists, diagnostic workflows, digital slides, and AI capabilities within an enterprise environment. Several Unilabs operations had already implemented Concentriq AP-Dx for routine case review, with additional deployments planned.

Deployment Modes Covered:

  • Cloud-Based Platforms
  • On-Premises Platforms
  • Hybrid Platforms

Platform Components Covered:

  • Software
  • Services

AI Functionalities Covered:

  • Automated Tissue & Cell Detection
  • Tumor Detection & Classification
  • Histological Grading & Quantification
  • Biomarker Detection & Scoring
  • Whole Slide Image Analysis
  • AI-Assisted Case Triage & Prioritization
  • Predictive Pathology & Prognostic Analytics
  • Pathology Workflow Automation
  • Other AI Functionalities

Clinical Applications Covered:

  • Oncology Pathology
  • Infectious Disease Pathology
  • Inflammatory & Autoimmune Disease Pathology
  • Neuropathology
  • Hematopathology
  • Transplant Pathology
  • Drug Discovery & Translational Research
  • Other Clinical Applications

End Users Covered:

  • Hospitals & Health Systems
  • Diagnostic & Reference Laboratories
  • Academic Medical Centers
  • Pharmaceutical & Biotechnology Companies
  • Contract Research Organizations
  • Research Institutes
  • Other End Users

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
      • Saudi Arabia
      • United Arab Emirates
      • Qatar
      • Israel
      • Rest of Middle East
    • Africa
      • South Africa
      • Egypt
      • Morocco
      • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global AI-Driven Digital Pathology Platforms Market, By Deployment Mode

  • 5.1 Cloud-Based Platforms
  • 5.2 On-Premises Platforms
  • 5.3 Hybrid Platforms

6 Global AI-Driven Digital Pathology Platforms Market, By Platform Component

  • 6.1 Software
    • 6.1.1 AI-Powered Pathology Image Analysis Software
    • 6.1.2 Digital Pathology Image Management Platforms
    • 6.1.3 Integrated AI Pathology Workflow Platforms
  • 6.2 Services
    • 6.2.1 Implementation & Integration Services
    • 6.2.2 Training & Consulting Services
    • 6.2.3 Support & Maintenance Services

7 Global AI-Driven Digital Pathology Platforms Market, By AI Functionality

  • 7.1 Automated Tissue & Cell Detection
  • 7.2 Tumor Detection & Classification
  • 7.3 Histological Grading & Quantification
  • 7.4 Biomarker Detection & Scoring
  • 7.5 Whole Slide Image Analysis
  • 7.6 AI-Assisted Case Triage & Prioritization
  • 7.7 Predictive Pathology & Prognostic Analytics
  • 7.8 Pathology Workflow Automation
  • 7.9 Other AI Functionalities

8 Global AI-Driven Digital Pathology Platforms Market, By Clinical Application

  • 8.1 Oncology Pathology
    • 8.1.1 Breast Cancer Pathology
    • 8.1.2 Prostate Cancer Pathology
    • 8.1.3 Other Cancer Pathology
  • 8.2 Infectious Disease Pathology
  • 8.3 Inflammatory & Autoimmune Disease Pathology
  • 8.4 Neuropathology
  • 8.5 Hematopathology
  • 8.6 Transplant Pathology
  • 8.7 Drug Discovery & Translational Research
  • 8.8 Other Clinical Applications

9 Global AI-Driven Digital Pathology Platforms Market, By End User

  • 9.1 Hospitals & Health Systems
  • 9.2 Diagnostic & Reference Laboratories
  • 9.3 Academic Medical Centers
  • 9.4 Pharmaceutical & Biotechnology Companies
  • 9.5 Contract Research Organizations
  • 9.6 Research Institutes
  • 9.7 Other End Users

10 Global AI-Driven Digital Pathology Platforms Market, By Geography

  • 10.1 North America
    • 10.1.1 United States
    • 10.1.2 Canada
    • 10.1.3 Mexico
  • 10.2 Europe
    • 10.2.1 United Kingdom
    • 10.2.2 Germany
    • 10.2.3 France
    • 10.2.4 Italy
    • 10.2.5 Spain
    • 10.2.6 Netherlands
    • 10.2.7 Belgium
    • 10.2.8 Sweden
    • 10.2.9 Switzerland
    • 10.2.10 Poland
    • 10.2.11 Rest of Europe
  • 10.3 Asia Pacific
    • 10.3.1 China
    • 10.3.2 Japan
    • 10.3.3 India
    • 10.3.4 South Korea
    • 10.3.5 Australia
    • 10.3.6 Indonesia
    • 10.3.7 Thailand
    • 10.3.8 Malaysia
    • 10.3.9 Singapore
    • 10.3.10 Vietnam
    • 10.3.11 Rest of Asia Pacific
  • 10.4 South America
    • 10.4.1 Brazil
    • 10.4.2 Argentina
    • 10.4.3 Colombia
    • 10.4.4 Chile
    • 10.4.5 Peru
    • 10.4.6 Rest of South America
  • 10.5 Rest of the World (RoW)
    • 10.5.1 Middle East
      • 10.5.1.1 Saudi Arabia
      • 10.5.1.2 United Arab Emirates
      • 10.5.1.3 Qatar
      • 10.5.1.4 Israel
      • 10.5.1.5 Rest of Middle East
    • 10.5.2 Africa
      • 10.5.2.1 South Africa
      • 10.5.2.2 Egypt
      • 10.5.2.3 Morocco
      • 10.5.2.4 Rest of Africa

11 Strategic Market Intelligence

  • 11.1 Industry Value Network and Supply Chain Assessment
  • 11.2 White-Space and Opportunity Mapping
  • 11.3 Product Evolution and Market Life Cycle Analysis
  • 11.4 Channel, Distributor, and Go-to-Market Assessment

12 Industry Developments and Strategic Initiatives

  • 12.1 Mergers and Acquisitions
  • 12.2 Partnerships, Alliances, and Joint Ventures
  • 12.3 New Product Launches and Certifications
  • 12.4 Capacity Expansion and Investments
  • 12.5 Other Strategic Initiatives

13 Company Profiles

  • 13.1 PathAI, Inc.
  • 13.2 Proscia Inc.
  • 13.3 Ibex Medical Analytics Ltd.
  • 13.4 Aiforia Technologies Plc
  • 13.5 Visiopharm A/S
  • 13.6 Indica Labs, Inc.
  • 13.7 Mindpeak GmbH
  • 13.8 Qritive
  • 13.9 Owkin, Inc.
  • 13.10 Nucleai, Inc.
  • 13.11 Techcyte, Inc.
  • 13.12 Deep Bio Inc.
  • 13.13 Tempus AI, Inc.
  • 13.14 Koninklijke Philips N.V.
  • 13.15 F. Hoffmann-La Roche Ltd.
  • 13.16 Leica Biosystems
  • 13.17 Hamamatsu Photonics K.K.
  • 13.18 Sectra AB

List of Tables

  • Table 1 Global AI-Driven Digital Pathology Platforms Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global AI-Driven Digital Pathology Platforms Market Outlook, By Deployment Mode (2023-2034) ($MN)
  • Table 3 Global AI-Driven Digital Pathology Platforms Market Outlook, By Cloud-Based Platforms (2023-2034) ($MN)
  • Table 4 Global AI-Driven Digital Pathology Platforms Market Outlook, By On-Premises Platforms (2023-2034) ($MN)
  • Table 5 Global AI-Driven Digital Pathology Platforms Market Outlook, By Hybrid Platforms (2023-2034) ($MN)
  • Table 6 Global AI-Driven Digital Pathology Platforms Market Outlook, By Platform Component (2023-2034) ($MN)
  • Table 7 Global AI-Driven Digital Pathology Platforms Market Outlook, By Software (2023-2034) ($MN)
  • Table 8 Global AI-Driven Digital Pathology Platforms Market Outlook, By AI-Powered Pathology Image Analysis Software (2023-2034) ($MN)
  • Table 9 Global AI-Driven Digital Pathology Platforms Market Outlook, By Digital Pathology Image Management Platforms (2023-2034) ($MN)
  • Table 10 Global AI-Driven Digital Pathology Platforms Market Outlook, By Integrated AI Pathology Workflow Platforms (2023-2034) ($MN)
  • Table 11 Global AI-Driven Digital Pathology Platforms Market Outlook, By Services (2023-2034) ($MN)
  • Table 12 Global AI-Driven Digital Pathology Platforms Market Outlook, By Implementation & Integration Services (2023-2034) ($MN)
  • Table 13 Global AI-Driven Digital Pathology Platforms Market Outlook, By Training & Consulting Services (2023-2034) ($MN)
  • Table 14 Global AI-Driven Digital Pathology Platforms Market Outlook, By Support & Maintenance Services (2023-2034) ($MN)
  • Table 15 Global AI-Driven Digital Pathology Platforms Market Outlook, By AI Functionality (2023-2034) ($MN)
  • Table 16 Global AI-Driven Digital Pathology Platforms Market Outlook, By Automated Tissue & Cell Detection (2023-2034) ($MN)
  • Table 17 Global AI-Driven Digital Pathology Platforms Market Outlook, By Tumor Detection & Classification (2023-2034) ($MN)
  • Table 18 Global AI-Driven Digital Pathology Platforms Market Outlook, By Histological Grading & Quantification (2023-2034) ($MN)
  • Table 19 Global AI-Driven Digital Pathology Platforms Market Outlook, By Biomarker Detection & Scoring (2023-2034) ($MN)
  • Table 20 Global AI-Driven Digital Pathology Platforms Market Outlook, By Whole Slide Image Analysis (2023-2034) ($MN)
  • Table 21 Global AI-Driven Digital Pathology Platforms Market Outlook, By AI-Assisted Case Triage & Prioritization (2023-2034) ($MN)
  • Table 22 Global AI-Driven Digital Pathology Platforms Market Outlook, By Predictive Pathology & Prognostic Analytics (2023-2034) ($MN)
  • Table 23 Global AI-Driven Digital Pathology Platforms Market Outlook, By Pathology Workflow Automation (2023-2034) ($MN)
  • Table 24 Global AI-Driven Digital Pathology Platforms Market Outlook, By Other AI Functionalities (2023-2034) ($MN)
  • Table 25 Global AI-Driven Digital Pathology Platforms Market Outlook, By Clinical Application (2023-2034) ($MN)
  • Table 26 Global AI-Driven Digital Pathology Platforms Market Outlook, By Oncology Pathology (2023-2034) ($MN)
  • Table 27 Global AI-Driven Digital Pathology Platforms Market Outlook, By Breast Cancer Pathology (2023-2034) ($MN)
  • Table 28 Global AI-Driven Digital Pathology Platforms Market Outlook, By Prostate Cancer Pathology (2023-2034) ($MN)
  • Table 29 Global AI-Driven Digital Pathology Platforms Market Outlook, By Other Cancer Pathology (2023-2034) ($MN)
  • Table 30 Global AI-Driven Digital Pathology Platforms Market Outlook, By Infectious Disease Pathology (2023-2034) ($MN)
  • Table 31 Global AI-Driven Digital Pathology Platforms Market Outlook, By Inflammatory & Autoimmune Disease Pathology (2023-2034) ($MN)
  • Table 32 Global AI-Driven Digital Pathology Platforms Market Outlook, By Neuropathology (2023-2034) ($MN)
  • Table 33 Global AI-Driven Digital Pathology Platforms Market Outlook, By Hematopathology (2023-2034) ($MN)
  • Table 34 Global AI-Driven Digital Pathology Platforms Market Outlook, By Transplant Pathology (2023-2034) ($MN)
  • Table 35 Global AI-Driven Digital Pathology Platforms Market Outlook, By Drug Discovery & Translational Research (2023-2034) ($MN)
  • Table 36 Global AI-Driven Digital Pathology Platforms Market Outlook, By Other Clinical Applications (2023-2034) ($MN)
  • Table 37 Global AI-Driven Digital Pathology Platforms Market Outlook, By End User (2023-2034) ($MN)
  • Table 38 Global AI-Driven Digital Pathology Platforms Market Outlook, By Hospitals & Health Systems (2023-2034) ($MN)
  • Table 39 Global AI-Driven Digital Pathology Platforms Market Outlook, By Diagnostic & Reference Laboratories (2023-2034) ($MN)
  • Table 40 Global AI-Driven Digital Pathology Platforms Market Outlook, By Academic Medical Centers (2023-2034) ($MN)
  • Table 41 Global AI-Driven Digital Pathology Platforms Market Outlook, By Pharmaceutical & Biotechnology Companies (2023-2034) ($MN)
  • Table 42 Global AI-Driven Digital Pathology Platforms Market Outlook, By Contract Research Organizations (2023-2034) ($MN)
  • Table 43 Global AI-Driven Digital Pathology Platforms Market Outlook, By Research Institutes (2023-2034) ($MN)
  • Table 44 Global AI-Driven Digital Pathology Platforms Market Outlook, By Other End Users (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.